Cite
HARVARD Citation
Hong, D. et al. (n.d.). 379 Initial safety, efficacy, and product attributes from the SURPASS trial with ADP-A2M4CD8, a SPEAR T-cell therapy incorporating an affinity optimized TCR targeting MAGE-A4 and a CD8α co-receptor. Journal for immunotherapy of cancer. p. A231. [Online].